从绝望到希望:解决帕金森病中的丧问题
Bradley McDaniels1, Ellen R Bradley2,3, Gregory Pontone4
1Department of Rehabilitation and Health Services, University of North Texas, Denton, Texas, USA.
Movement disorders clinical practice
|July 1, 2025
概括
帕金森病 (PD) 中的丧气与抑郁症不同,影响生活质量. 建议采用富有同情心的多学科方法,以获得有效的干预和更好的结果.
科学领域:
- 神经学 神经学
- 精神病学是一个精神病学.
- 生活质量研究 研究 生命质量研究
背景情况:
- 丧气是一种常见的绝望和动机丧失综合征,经常被误诊为抑郁症.
- 它影响了超过三分之一的医疗机构和20-30%的普通人口.
- 在帕金森病 (PD) 中,抑郁症显著影响生活质量,社会参与和治疗坚持.
研究的目的:
- 综合有关异常病理病的士气丧失的文献.
- 为了界定它的流行,现象学和相关性.
- 澄清与抑郁和冷漠的区别,并提供干预建议.
主要方法:
- 在主要数据库 (MEDLINE,Embase,PsycINFO,Web of Science) 进行有针对性的文献搜索.
- 手动参考选,以确定符合条件的经验和概念研究.
- 鉴于设计异质性,对已识别的研究进行主题综合.
主要成果:
- 七篇论文满足了在异常病态PD中丧气的搜索标准.
- 识别的文献进行了合成,以探索这一现象.
结论:
- 在患有PD (PWP) 的人群中,丧与抑郁症在临床上是不同的.
- 基于证据的干预措施应该是富有同情心,多学科和个性化的.
- 解决PD的社会和心理方面可以减轻丧,改善生活质量和功能结果.
相关概念视频
Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
Parkinson's Disease: Treatment
389
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
389
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107


